Appendices to: Observations Regarding the Average Sales Price Reimbursement Methodology
FDA Approves Sacituzumab Govitecan for Pre-Treated HR+/HER2- Metastatic Breast Cancer
February 3rd 2023The approval is based on results from the phase 3 TROPiCS-02 trial demonstrating overall and progression survival benefits with sacituzumab govitecan compared with physician’s choice of single-agent chemotherapy.
Read More
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
Artificial Intelligence May Help Differentiate Colon Carcinoma From Acute Diverticulitis
January 27th 2023Colon carcinoma and acute diverticulitis have similar computed tomography imaging features that can make differential diagnosis difficult for radiologists, but a novel artificial intelligence assistance model was shown to help diagnostic accuracy.
Read More
Interstitial Lung Abnormalities Impact OS in NSCLC Patients Receiving CRT, Adjuvant Durvalumab
January 19th 2023Pretreatment interstitial lung abnormalities were associated with worse overall and cause-specific survival in Japanese patients receiving chemoradiotherapy followed by adjuvant durvalumab for locally advanced non–small-cell lung cancer.
Read More
2 Clarke Drive
Cranbury, NJ 08512